TW200716670A - Use of panton-valentine leukocidin for treating and preventing staphylococcus infections - Google Patents

Use of panton-valentine leukocidin for treating and preventing staphylococcus infections

Info

Publication number
TW200716670A
TW200716670A TW095121049A TW95121049A TW200716670A TW 200716670 A TW200716670 A TW 200716670A TW 095121049 A TW095121049 A TW 095121049A TW 95121049 A TW95121049 A TW 95121049A TW 200716670 A TW200716670 A TW 200716670A
Authority
TW
Taiwan
Prior art keywords
pvl
treating
panton
infections
methods
Prior art date
Application number
TW095121049A
Other languages
English (en)
Other versions
TWI374892B (en
Inventor
Kimberly Louise Taylor
Ali Ibrahim Fattom
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of TW200716670A publication Critical patent/TW200716670A/zh
Application granted granted Critical
Publication of TWI374892B publication Critical patent/TWI374892B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095121049A 2005-06-13 2006-06-13 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections TWI374892B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68952605P 2005-06-13 2005-06-13

Publications (2)

Publication Number Publication Date
TW200716670A true TW200716670A (en) 2007-05-01
TWI374892B TWI374892B (en) 2012-10-21

Family

ID=37440793

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095121049A TWI374892B (en) 2005-06-13 2006-06-13 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections

Country Status (12)

Country Link
US (1) US20090074755A1 (zh)
EP (2) EP1915396A2 (zh)
JP (1) JP5096326B2 (zh)
KR (1) KR101302764B1 (zh)
CN (2) CN101218252A (zh)
AR (1) AR055580A1 (zh)
AU (1) AU2006257774B2 (zh)
CA (1) CA2611023A1 (zh)
MX (1) MX2007015758A (zh)
NZ (1) NZ565069A (zh)
TW (1) TWI374892B (zh)
WO (1) WO2006135912A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
KR20090019007A (ko) * 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
FR2912219A1 (fr) * 2007-02-06 2008-08-08 Biomerieux Sa Procede de diagnostic in vitro des staphylococcus aureus producteurs de pvl, anticorps monoclonaux et kits de diagnostic
US8936791B2 (en) 2006-10-18 2015-01-20 Biomerieux Method for in vitro diagnosis of PVL-producing Staphylococcus aureus
US20110251162A1 (en) * 2008-09-25 2011-10-13 Cedars-Sinai Medical Center Methods of treatment for mrsa infections
MX364642B (es) * 2010-05-05 2019-05-03 Univ New York Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
US9316640B2 (en) * 2011-11-11 2016-04-19 Alere San Diego, Inc. Devices and methods for detection of Panton-Valentine Leukocidin (PVL)
AU2012345645B2 (en) * 2011-12-02 2017-09-07 Abvacc, Inc. Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN107224576A (zh) * 2017-03-06 2017-10-03 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位的疫苗及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
AU681573B2 (en) 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
JP2000316574A (ja) * 1999-03-10 2000-11-21 Matsushita Seiko Co Ltd Ｍｒｓａが産生する毒素タンパクの検出方法およびモノクローナル抗体とその断片およびｍｒｓａが産生する毒素タンパク検出用キットおよびモノクローナル抗体を産生するハイブリドーマ
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
EP1608756B1 (en) * 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigens
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
KR20090019007A (ko) * 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도

Also Published As

Publication number Publication date
NZ565069A (en) 2011-08-26
CN101218252A (zh) 2008-07-09
JP2008546648A (ja) 2008-12-25
KR101302764B1 (ko) 2013-09-02
EP2289938A2 (en) 2011-03-02
AU2006257774B2 (en) 2012-03-01
AR055580A1 (es) 2007-08-29
WO2006135912A2 (en) 2006-12-21
MX2007015758A (es) 2008-02-22
WO2006135912A3 (en) 2007-05-24
EP1915396A2 (en) 2008-04-30
KR20080016956A (ko) 2008-02-22
AU2006257774A1 (en) 2006-12-21
US20090074755A1 (en) 2009-03-19
TWI374892B (en) 2012-10-21
EP2289938A3 (en) 2011-04-06
CA2611023A1 (en) 2006-12-21
JP5096326B2 (ja) 2012-12-12
CN102698261A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
TW200716670A (en) Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
TW200744632A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
PH12018501891A1 (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
BRPI0519232A2 (pt) vacinas de conjugados de sacarÍdeos
TW200626171A (en) Fixed dosing of HER antibodies
TW200732349A (en) Anti-OX40L antibodies and methods using same
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2013006960A (es) Composicion inmunogenica estable de antigenos de staphylococcus aureus.
MY175687A (en) Composition comprising two antibodies engineered to have reduced and increased effector function
TW200642694A (en) Anti-M-CSF antibody compositions
TN2010000213A1 (en) Wise binding antibodies and epitopes
UA92505C2 (ru) Композиции на основе антитела против cd3
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2010065735A3 (en) Methods and compositions for treating p.acnes
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
EP2749570A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2016000195A (es) Oligosacaridos sinteticos para vacuna de p. aeruginosa.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees